Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
TROPION-Urothelial04 trial: what clinicians have said so far
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
- NCT07720284 ↗
- Recruiting
- AstraZeneca
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on TROPION-Urothelial04 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TROPION-Urothelial04 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- High-risk Muscle Invasive Urothelial Carcinoma
- Interventions
- Dato-DXd; Rilvegostomig; Durvalumab; Nivolumab; Pembrolizumab; Enfortumab vedotin
- Arms
- Arm 1: Dato-DXd + rilvegostomig · Experimental
- Arm 2: Dato-DXd monotherapy · Experimental
- Arm 3 (SoC): nivolumab or durvalumab or EV + pembrolizumab · Active comparator
- Enrollment
- 915 (estimated)
- Primary outcomes
- To demonstrate the superiority of Dato-DXd + rilvegostomig (Arm 1) relative to SoC (Arm 3) by assessment of disease-free survival (DFS) (based on Investigator assessments).
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Jul 16, 2026
- Primary completion
- Sep 11, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT07720284 · updated Jul 22, 2026